With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

2.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Benzene in Cold Med; Male Cancer Death to Rise 93%; Mail-Order Drugs Compromised?

5.

New research demonstrates a method for screening people at high risk for pancreatic cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot